Lead Sponsor

Scott and White Hospital & Clinic

Collaborators

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

•1. Patients with Type 2 diabetes and CKD
•2. Age 18 - 70 years
•3. Stable anti-hypertensive and lipid lowering therapy for at least 2 months. All patients should be on an ACEI or ARB unless contraindicated because of side effects (standard of care). No changes in lipid lowering therapy during the 3 months of this study. Blood pressure doses may be changed but new therapy with ACE inhibitors will not be allowed.

•1. Severe co morbid conditions - e.g. Cancer, etc.
•2. Congestive heart failure.
•3. Inability to give informed consent or attend study related visits.
•4. Have a history of abnormally high vitamin D or calcium levels in the bloodstream.
•5. Unwilling or unable to complete screening or data collection procedures.
•6. Have a known allergy to the study drug.
•7. Pregnant or breast feeding
•8. Plasma Calcium \>9 mg/dl
•9. Patients should discontinue any calcium supplementation prior to entry into the study.
•10. Other vitamin D analogs (eg Sensipar) and vitamin D preparations are contraindicated